Combination - Brigatinib (Alunbrig™) & Bevacizumab (Avastin™)

Status: Solid Tumor and NF2 Clinical Trial

Legal Status:

℞ - Trial

Administered By:

Pill - Oral, And IV

Tumor Target:

Solid Tumors; Schwannoma, Meningioma, & possibly Ependymoma

Inhibits:

anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR) inhibitor

Brigatinib (Alunbrig™) is a clinical trial tumor drug treatment listed for solid tumors. Early mouse trial studies suggest brigatinib may have good results with the reduction of size in solid tumors including; schwannoma and meningioma.

During the mouse trials no growth was seen with long treatment breaks, followed by continued size reduction when the treatment continued again later. If this holds for human trials, breaks for healing from possible side effects or for treatments of other health issues.

Treatment Availability

Results in the Mouse Trial Phase

Side Effects

Source Information

• "Clinical Trials" ()
  https://clinicaltrials.gov// "Google Scholar" ()
  https://scholar.google.com/